Published

Comparison of solution conformational preferences for the hallucinogens bufotenin and psilocin using 360-MHz proton NMR spectroscopy

An abstract is available from the original source but is not redistributed by this tracker. Read the source record.

Open source BibTeX RIS

Bibliographic context

Journal: Journal of Medicinal Chemistry
Date: 1981-02-01
Source: Crossref
DOI: 10.1021/jm00134a016
PubMed: 6259355

Authors

Migliaccio Gerald P.Shieh Tiee-Leou N.Byrn Stephen R.Hathaway Bruce A.Nichols David E.

Watch author

Derived topics and classifications

psilocin General Other

Citation graph

0 referenced DOIs found in stored source metadata. 8 indexed papers cite this DOI.

Open citation network

Indexed papers citing this DOI

Design, Synthesis, and Pharmacokinetic Profiling of Fluorinated Reversible N -Alkyl Carbamate Derivatives of Psilocin for Sub-Hallucinogenic Brain Exposure2026-02-12 Efficient Acyloxymethylation of Psilocin and Other Tryptamines Yielding ACOM Prodrugs for Psychedelic-Assisted Therapy2025-07-01 Clinical Pharmacokinetics of Psilocin After Psilocybin Administration: A Systematic Review and Post-Hoc Analysis2025-01-01 The molecular basis of the antidepressant action of the magic mushroom extract, psilocin2023-07-01 Assessment of Bioactivity-Modulating Pseudo-Ring Formation in Psilocin and Related Tryptamines2022-07-05 Glucuronidation of Psilocin and 4-Hydroxyindole by the Human UDP-Glucuronosyltransferases2010-03-01 ChemInform Abstract: COMPARISON OF SOLUTION CONFORMATIONAL PREFERENCES FOR THE HALLUCINOGENS BUFOTENIN AND PSILOCIN USING 360-MHZ PROTON NMR SPECTROSCOPY1981-07-14 Comparison of solution conformational preferences for the hallucinogens bufotenin and psilocin using 360-MHz proton NMR spectroscopy1981-02-01

Related papers

A Phase III, Multicentre, Randomised, Double-blind, Controlled Study to Investigate the Efficacy, Safety, and Tolerability of Two Administrations of COMP360 in Participants With Treatment-resistant DepressionClinicalTrials.gov · 2026-08-10 A Phase III, Multicentre, Randomised, Double-blind, Placebo-controlled Study to Investigate the Efficacy, Safety, and Tolerability of COMP360 in Participants With Treatment-resistant DepressionClinicalTrials.gov · 2026-08-10 A Phase 3, Randomized, Double-Blind, Multicenter Study to Evaluate the Efficacy, Safety, and Tolerability of Psilocybin in Adults With Major Depressive Disorder (MDD)ClinicalTrials.gov · 2026-07-23 A Phase II, Multicentre, Randomised, Double-blind, Controlled Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Efficacy of COMP360 in Participants With Recurrent Major Depressive DisorderClinicalTrials.gov · 2025-08-19